Ocular Therapeutix (NASDAQ:OCUL) Insider Peter Kaiser Sells 9,653 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Peter Kaiser sold 9,653 shares of the firm’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $11.03, for a total transaction of $106,472.59. Following the completion of the sale, the insider directly owned 194,440 shares of the company’s stock, valued at approximately $2,144,673.20. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Peter Kaiser also recently made the following trade(s):

• On Monday, August 25th, Peter Kaiser sold 3,011 shares of Ocular Therapeutix stock. The shares were sold at an average price of $12.04, for a total transaction of $36,252.44.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $10.97 on Tuesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.10 and a quick ratio of 10.02. Ocular Therapeutix, Inc. has a one year low of $5.78 and a one year high of $13.85. The company has a 50-day simple moving average of $12.28 and a two-hundred day simple moving average of $9.77. The firm has a market capitalization of $1.91 billion, a PE ratio of -8.57 and a beta of 1.45.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The firm had revenue of $13.46 million for the quarter, compared to analysts’ expectations of $13.12 million. Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The firm’s revenue was down 17.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.26) EPS. On average, analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Saturday, September 27th. Robert W. Baird increased their price target on shares of Ocular Therapeutix from $17.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday. Scotiabank dropped their price objective on shares of Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating on the stock in a research note on Wednesday, August 6th. Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 2nd. Finally, Piper Sandler boosted their price target on Ocular Therapeutix from $21.00 to $31.00 and gave the stock an “overweight” rating in a research report on Friday. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.13.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in OCUL. Adage Capital Partners GP L.L.C. grew its holdings in shares of Ocular Therapeutix by 44.4% during the first quarter. Adage Capital Partners GP L.L.C. now owns 5,200,000 shares of the biopharmaceutical company’s stock valued at $38,116,000 after buying an additional 1,600,000 shares during the last quarter. Paradigm Biocapital Advisors LP bought a new position in Ocular Therapeutix in the 1st quarter valued at approximately $9,632,000. Peregrine Capital Management LLC purchased a new stake in Ocular Therapeutix during the 1st quarter valued at $6,212,000. Invesco Ltd. increased its holdings in shares of Ocular Therapeutix by 91.2% in the 2nd quarter. Invesco Ltd. now owns 1,538,846 shares of the biopharmaceutical company’s stock worth $14,280,000 after purchasing an additional 734,017 shares in the last quarter. Finally, Raymond James Financial Inc. raised its stake in shares of Ocular Therapeutix by 142.8% in the second quarter. Raymond James Financial Inc. now owns 884,381 shares of the biopharmaceutical company’s stock worth $8,207,000 after purchasing an additional 520,138 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.